Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 266 participants.

Also called NCT01336738

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 266 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01336738
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Hungary, Mexico, Slovakia, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01336738. Randomized; double masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2013-08-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
Condition
Diabetes, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
150 mg PF-04991532
Intervention (Drug)
450 mg PF-04991532
Intervention (Drug)
750 mg PF-04991532
Intervention (Drug)
Sitagliptin 100 mg
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01336738
Content hash
d491c89402b8c4823ad81b02c2493a8054af50eb4a7c3b5370cfc076e72c0bc1